Stocks Health care INDP
NASDAQ · Health careIndaptus Therapeutics, Inc. (INDP)
It posted a net loss of $15.4M. At June 30, 2026 it held $7.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
What Indaptus Therapeutics, Inc. does
Indaptus Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INDP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$20.8M | -$21.58 | n/a |
| 2024 | n/a | -$15M | -$44.96 | n/a |
| 2023 | n/a | -$15.4M | -$51.10 | n/a |
| 2022 | n/a | -$14.3M | -$48.31 | n/a |
| 2021 | n/a | -$7.7M | -$52.78 | -$11.3M |
| 2021 | n/a | -$3.6M | -$51.38 | n/a |
Latest SEC filings
What Indaptus Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 10, 2026
- September 8, 2026Material agreement 8-K/A
- September 4, 2026
- September 4, 2026
- September 1, 2026
- August 31, 2026
- August 26, 2026
- August 17, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026
- August 13, 2026
Questions about INDP
What does Indaptus Therapeutics, Inc. do?
Indaptus Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker INDP.
Is Indaptus Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $15.4M.
When did Indaptus Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 10, 2026.
Similar companies
Follow INDP
Get an email when Indaptus Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow INDP: get an email when it filesWhere the numbers come from
Financial figures are the values Indaptus Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.